ORAL ACYCLOVIR IN NEONATAL HERPEX SIMPLEX

口服阿昔洛韦治疗新生儿单纯疱疹

• 批准号: 7603163
• 负责人: DAVID W KIMBERLIN
• 金额: $ 0.33万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603163
• 关键词: Acyclovir; Clinical; Computer Retrieval of Information on Scientific Projects Database; Cutaneous; Development; Eye; Family; Funding; Grant; Infant; Infection; Institution; Laboratories; Lesion; Monitor; Mouth Diseases; Neonatal; Neurological outcome; Nursing Staff; Oral; Oral Administration; Oral cavity; Polymerase Chain Reaction; Recurrence; Research; Research Infrastructure; Research Personnel; Resistance; Resources; Safety; Skin; Source; Suspension substance; Suspensions; Testing; Time; United States National Institutes of Health; Variant; Viral; cohort; improved

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will evaluate the efficacy of long-term suppressive therapy with oral acyclovir in infants with neonatal herpes infections limited to the skin, eye, or mouth (SEM). It will determine if suppressive oral acyclovir therapy improves neurologic outcome in infants following SEM disease. Additionally, it will determine if continuous administration of oral acyclovir suspension suppresses recurrent skin lesions in infants following SEM disease. It will confirm the safety of long-term administration of oral acyclovir therapy in a cohort of infants with SEM disease. The significance of positive CSF PCR results at the time of cutaneous recurrences will be assessed, and the development of viral variants resistant to acyclovir monitored and characterized. Finally, the effects of suppressive acyclovir therapy on issues of pharmocoeconomics and family infrastructure will be assessed and quantitated. The GCRC is utilized by providing clinical space, nursing staff, funding specialized testing and laboratory support.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究将评价长期口服阿昔洛韦抑制治疗局限于皮肤、眼睛或口腔（SEM）的新生儿疱疹感染的疗效。 它将确定是否抑制性口服阿昔洛韦治疗改善神经功能的结果在婴儿以下SEM疾病。 此外，它将确定口服阿昔洛韦混悬液连续给药是否能抑制SEM疾病后婴儿皮肤病变的复发。 它将证实长期口服阿昔洛韦治疗SEM疾病婴儿的安全性。 将评估皮肤复发时阳性CSF PCR结果的意义，并监测和表征对阿昔洛韦耐药的病毒变体的发展。 最后，将评估和量化抑制性阿昔洛韦治疗对药物经济学和家庭基础设施问题的影响。 GCRC通过提供临床空间，护理人员，资助专业测试和实验室支持来利用。